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Abstract
Leukemia is cancer of the blood and bone marrow, it is the most common cancer found in children and is found to
be more than one fourth of pediatric cancers. It causes white blood cells to become abnormal and the body to
become weak. This deficiency in the immune system reduces the body's ability to fight infection or simple airborne
illnesses, causing extensive treatment of common pathogens and cancer treatment. The present review covers all
topics, from diagnosis to treatment of pediatric leukemia, as well as the stages of growth and physiological changes
throughout the process. As leukemia has a high mortality rate the chances of survival are low. Discussion on survival
rate will be breached and thoroughly deciphered. We also included the topic of treatment and at which point patients
may be considered terminal or advanced. By approaching these points, we better understand leukemia (from a
scientific standpoint) and its properties throughout the course of treatment.
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Introduction
Pediatric leukemia is one of the deadliest cancers, with one of the
highest mortality rates throughout the globe. There are two major
types of pediatric leukemia, Acute Lymphocytic (ALL) and Acute
Myelogenous (AML). When a child has ALL, fully mature white blood
cells are not able to form properly, therefore the patient is not able to
fend off illnesses (such as the common cold) well and may become
terminal from such ailment. White blood cells help us fight off
infection. In the case of leukemia patients, white blood cells form
abnormally and stem cells turn into lymphoblast (leukemia cells). This
causes backlash on the body by decreasing the number of red blood
cells and platelets the bones can produce. Red blood cells are the main
reason for blood clotting, infection resistance, and iron retention [1-3].
Without functional red blood cells, heavy bleeding from a simple
wound or anemia is possible.
An excess of myoblasts in the body causes acute myelogenous
leukemia. Myoblasts, like lymphoblast are abnormally produced white
blood cells that cause fast acting deterioration in patients. Since
children’s bodies are still growing and becoming accustomed to
variations, leukemia in children tends to be acute and often becomes
advanced/terminal. Chronic leukemia is generally diagnosed in
patients who have reached adulthood and are no longer physically
growing.
Signs, Symptoms, and Stages
Other diseases or other internal problems may cause the signs and
symptoms of pediatric leukemia. Symptoms of pediatric leukemia may
include anemia, weakness, feeling cold, pale skin, and shortness of
breath. Symptoms are more prominent from low white blood cell
counts. Low white blood cell count may cause infections, fevers, and
low immunity. If a child gets an infection, and it persists over a long
period of time, or gets one infection after another, it could be a
symptom of childhood leukemia. The cancerous cells fight of the
normal cells that protect the body’s immunity. With low immunity
comes more infection and inflammation. Joint pain and the swelling of
the exterior of the stomach are caused by the collection of leukemia
cells along the surface. Due to this, symptoms may impact appetite and
weight. Swollen lymph nodes suggest a widespread of inflammation,
but very inflamed lymph nodes can suggest that there is cancer in the
body. Gradual inflammation occurring in different parts of the body
may also display signs of cancer. The last sign of pediatric leukemia is
extreme fatigue and weakness. In this case, leukemia cells have
bombarded the blood circulation and they become so thick that they
deplete blood flow to other organs, but most importantly to the brain.
Although some of the symptoms associated with pediatric leukemia
may be symptoms of other diseases, a doctor must examine those
symptoms for the disease to be treated correctly.
Leukemia cells populate so quickly that the stages of leukemia are
divided into sub-types. Acute leukemia is staged based on the types of
cells involved and the appearance of the cells microscopically.
Lymphocytic types of leukemia occur in lymphocytes. In this case, the
white blood count is taken in to consideration. Due to the quick
production of white blood cells in leukemia, specialists can detect the
stage of the leukemia based on how many white blood cells are present
around specific organs such as the spleen or the liver. Another type of
leukemia is myeloid leukemia, where the diagnosis is based on the
number of immature white blood cells, which can be found in either
the bone marrow or in the blood [2].
Epidemiology
In the United States, about 16,000 children between the age of 0 and
19 are diagnosed with some form of cancer [4-6]. However, because
pediatric cancers are diagnosed early, the survival rates are higher.
Doctors recommend that children get regular check-ups so that no
sign is overlooked concerning the development of recurring
symptoms. Although the cause for cancer is unknown, genetics play a
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role in children developing cancer. More than about 40,000 children
undergo treatment for cancer annually [4]. Children that are 6 years
old are on average diagnosed the most as shown in (Figure 1) [7-9].
Figure 1: Pediatric Leukemia Statistics.
The Treatments of Childhood Acute Lymphoblastic
Leukemia (Pediatric Leukemia)
There are different types of treatments for children with acute
lymphoblastic leukemia that are accessible. The treatments presently
used are radiation and chemotherapy, while other treatments must be
tested in clinical trials. Clinical trials for treatment develop the existing
treatments and gain more information for new treatments. An expert
team of doctors who have the best knowledge of the childhood
leukemia symptoms must plan all treatments. A pediatric oncologist is
a specialized doctor in childhood leukemia, who works with other
health professionals that have authority on treating children with
leukemia. The health professional team should include: Pediatrician,
Hematologist, medical oncologist, pediatric surgeon, radiation
oncologist, neurologist, pathologist, radiologist, pediatric nurse
specialist, child-life specialist and psychologist [3,9].
The three phases of pediatric leukemia treatments
1. Remission induction: it is the first phase of pediatric leukemia
treatment. The purpose is killing the leukemia cancer cells in the
blood and bone marrow, which placed the leukemia into a cancer
reduction.
2. Consolidation/intensification therapy: it is the second phase of
pediatric leukemia treatment. It starts after the leukemia is in the
remission phase. The purpose is killing any leukemia cancer cells
that remained in the body and it may lead to retrogression.
3. Maintenance: it is the third phase of pediatric leukemia
treatment. The purpose is killing leukemia cancer cells that might
regrow and to prevent retrogression. Frequently, the leukemia
treatment is provided in lower doses, which are lower than the
dosage during the remission induction and consolidation/
intensification therapy phases. In this phase, if the medication is
not taken, as it should, it can increase the chance for the cancer to
come back. This phase is also considered as the continuation
therapy phase [3].
The four standard treatment types of pediatric leukemia
Since leukemia may affect red and white blood cells and platelets as
well, doctors must do their diagnoses based on physical exams and
history, complete blood count with differential, blood chemistry
studies and bone marrow aspiration and biopsy. These types of testing
are helping the treatment determination options:
1. Chemotherapy is the most common cancer treatment that uses
drugs to stop the cancer cells from growing either by stopping the
division or by killing the cancer cells. Intrathecal chemotherapy
can be used for treating leukemia that has spread or may reach
the spinal cord or the brain.
2. Radiation therapy is one of the cancer treatments that use high-
energy radiation like x-rays to kill cancer cells or stop the growth
of cancer cells. The therapy has two radiation types; external
radiation therapy that uses machines from outside of the human
body to send radiation toward cancer cells, and internal radiation
therapy that uses a radioactive substance bolted in seeds, wires,
needles, or catheters which are placed near or inside cancer cells.
Radiation therapy depends on the type of cancer that is needed to
be treated.
3. Chemotherapy with stem cell transplant includes giving high
doses of chemotherapy and replacing the bad blood-forming
cells. The therapy is about removing stem cells from the bone
marrow or the blood of a donor; the stem cells will be given to
the patient through an infusion.
4. Targeted therapy uses drugs or similar substances to distinguish
and offensive specific cancer cells only without any negative effect
on normal cells. Targeted therapy drugs are such as Tyrosine
Kinase Inhibitors (TKIs) and Monoclonal antibody therapies [5].
The clinical trials can be done to help cancer from coming back or
reducing the side effects of the cancer treatments. All the treatment
and clinical trials in the first place are depending on the prognosis and
the doctor’s orders for treatments. Risk factor is any risk that increase
the opportunity of getting a disease but it doesn’t mean that will be a
cancer. Risk factor may include, exposing to radiation, past treatment
of chemotherapy, smoking, or eating contaminated food. Pediatric
leukemia is so expansive to treat and also depends on the type, phase
and the stage of the treatment. It is extremely costly so often times the
government gives free Medicare for people who cannot afford it [5,6].
Discussion and Conclusion
Understanding the key differences (or similarities) of Acute
Lymphocytic and Acute Myelogenous Leukemia is the first step
towards not only increasing awareness but also decreasing mortalities
due to these cancers. The continued awareness of these diseases in
every aspect allow us to further research to advance medical
procedures, develop technologies, and not least importantly further
research into areas that would have been out of reach to us. For
example, the team of Thomas Pabst and Linda Kurtz recently
published a study concerning the role lipids might play in "the
heterogeneity and outcome of disease".
Prior research that discovered certain lipids being lower in presence
in the cells of AML; also, coupled with the fact that most research is
being exhausted in understanding signalling cascades, was the primary
motive behind their research. Their work took them into studying
several plasma lipids concluding that there are various lipids that are
considerably altered in patients suffering from AML. Total cholesterol,
Citation: Bernard SC, Abdelsamad EH, Johnson PA, Chapman DL, Parvathaneni M (2017) Pediatric Leukemia: Diagnosis to Treatment–A
Review. J Cancer Clin Trials 2: 131. 
Page 2 of 3
J Cancer Clin Trials, an open access journal Volume 2 • Issue 2 • 1000131
phospholipids, sphingolipids, and cholesterol esters emphasize to the
range of the altered lipid profile. Specifically, eicosanoids (a class of
hormone like fatty acids produced from arachidonic acid) positively
correlate to not only a strong indication of the disease; however, it also
positively correlates to the severity of the disease.
Not to be all negative, the study also discovered that a lipid
indicated plasma PGF2α may act as a marker at the time of diagnosis
for limited disease severity. The furthered advancement doesn't just
stop with our continued understanding of AML or Acute Lymphocytic
Leukemia (ALL). A study by Man, Morris and Keng provides a
comprehensive review of all the new therapeutic strategies in ALL. Last
year alone (2016) 171,500 people were expected to be diagnosed with
some form of Leukemia; subsequently, tens of thousands of people die
from this disease every year. With continued research and
understanding we can hopefully, not only decrease the amount of
people dying from this disease but maybe, the amount of people who
have it.
References
1. https://www.cancer.org/cancer/leukemia-in-children/detection-
diagnosis-staging/signs-and-symptoms.html
2. http://www.cancercenter.com/leukemia/stages/?
source=GGLPS01&channel=paid
+search&invsrc=Non_Branded_Paid_Search_Google_Cancer_Search&u
tm_device=c&utm_budget=Corporate&utm_site=GOOGLE&utm_camp
aign=Non+Brand%3ECancer+Type%3A
+Leukemia&utm_adgroup=Stages%3EGeneral%3EBroad&utm_term=
%2Bleukemia+%2Bstages&utm_matchtype=b&k_clickid=fdfdf184-
add8-4450-8873-4e5f5bbf1c23&k_profid=422&k_kwid=407669
3. https://www.cancer.gov/types/leukemia/patient/child-all-treatment-
pdq#section/_32
4. https://curesearch.org/Childhood-Cancer-Statistics?
gclid=Cj0KEQjwwoLHBRDD0beVheu3lt0BEiQAvU4CKiwAzZsvHogue
QAFCrMccAs9H9Ce0aL7Amsy4IsGy-YaArgQ8P8HAQ
5. Cooper SL, Brown PA (2015) Treatment of Pediatric Acute Lymphoblastic
Leukemia. Pediatric Clinics of North America 62: 61-73.
6. http://www.allbloodcancers.org/leukemia?
gclid=Cj0KEQjwwoLHBRDD0beVheu3lt0BEiQAvU4CKtJKoOyhOTsY4
SWY2F600QqEC3EIm6k86LGpCfQk24saAurP8P8HAQ
7. Man LM, Morris AL, Keng M (2017). New Therapeutic Strategies in
Acute Lymphocytic Leukemia. Current Hematologic Malignancy
Reports.
8. Pabst T, Kortz L, Fiedler GM, Ceglarek U, Idle JR, et al. (2017) The plasma
lipidome in acute myeloid leukemia at diagnosis in relation to clinical
disease features. BBA Clinical 7: 105-114. 
9. http://www.lymphomation.org/images/childhood-nhy-pie1.gif
 
Citation: Bernard SC, Abdelsamad EH, Johnson PA, Chapman DL, Parvathaneni M (2017) Pediatric Leukemia: Diagnosis to Treatment–A
Review. J Cancer Clin Trials 2: 131. 
Page 3 of 3
J Cancer Clin Trials, an open access journal Volume 2 • Issue 2 • 1000131
